New study reviews how chinese patients actually use lung cancer drug lorlatinib
NCT ID NCT07556549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 50 Chinese adults with advanced ALK-positive non-small cell lung cancer who received lorlatinib as their first treatment. Researchers want to learn about patient characteristics, such as age and smoking history, and how the drug is used in real-world clinics. The goal is to gather information, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorlatinib
What this could lead to
If successful, this study could help doctors understand how lorlatinib is used in everyday practice in China, potentially guiding better treatment decisions for ALK-positive lung cancer patients.
What could go wrong
This is a retrospective chart review, not a controlled trial, so it cannot prove cause and effect. Results may be limited by incomplete records or small sample size (50 patients).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Beijing, China